No active regulatory warningsFDA MedWatch, EMA EudraVigilance, WHO VigiBase, WADA Prohibited List · 2026-05-29
Updated: 2026-05-29 · v2.0 · Prof. G. Pkhakadze, MD, MPH, PhDCiteEditorial
📰Read the full Coenzyme Q10 evidence review on GMJ News →Complete clinical article, references and updates on news.gmj.ge. This page is the structured safety summary.
1
Safe
Coenzyme Q10
Ubiquinone / Ubiquinol
Generally SafeModerateVitamin-Like
RDA
Typical 100–300 mg
Target
>1.0 µg/mL; >2.0 µg/mL
Upper limit
Studied up to 1,200 mg
Products
43
Dosage by population group — reference
🔗 Best with: Vitamin E, Selenium, Alpha-Lipoic Acid✅ USP Verified, NSF Contents Certified, ConsumerLab Approved
⚠ Statin patient with persistent myalgia — trial of CoQ10 100–200 mg/day is reasonable [8]
⚠ Heart failure patient — Q-SYMBIO showed mortality benefit at 300 mg/day; discuss with cardiologist [5]
⚠ Warfarin patient starting CoQ10 — structurally similar to vitamin K; check INR within 1–2 weeks [3]
⚠ Child with steroid-resistant nephrotic syndrome or cerebellar ataxia — consider primary CoQ10 deficiency [4]
⚠ PD patient asking about CoQ10 — QE3 trial showed no benefit; redirect to evidence-based therapies [6]
ℹ️ Not obtained from food. Made by the body and present in small amounts in food; there is no established daily dietary target.
☑ Risk checker
Statin therapy (inhibits mevalonate pathway, reducing CoQ10 synthesis by 20–40%) [2]
Aging (endogenous synthesis declines after age 30–40) [3]
Heart failure (increased utilization, reduced tissue levels) [5]
Primary CoQ10 deficiency (autosomal recessive mutations in COQ genes) [4]
Mitochondrial disorders [4]
Select factors
🔬 Lab interpreter
Recommended test
Plasma CoQ10 (total ubiquinone + ubiquinol)
Reference range / target
>1.0 µg/mL (therapeutic); >2.0 µg/mL (some cardiology targets)
When to test
If monitoring supplementation response in heart failure or primary deficiency [3].
Plasma CoQ10 reflects supplementation status, not tissue status. Levels rise with supplementation and return to baseline within 2 weeks of stopping [3].
Full lab monitoring ↓
⚕ For professionals — confirm ranges against your local laboratory.
Clinical verdict
CoQ10 is a critical mitochondrial electron carrier whose synthesis is reduced 20–40% by statins. Q-SYMBIO trial showed 43% MACE reduction in heart failure at 300 mg/day. No benefit proven for Parkinson disease (QE3 trial). Ubiquinol is 2–3× more bioavailable than ubiquinone. Take with fat-containing meals. Monitor INR if on warfarin [2] [5] [6].
1 How much do I need?
👤 Adults: Specific dosage data under clinical review
👴 Elderly: Specific dosage data under clinical review
🤰 Pregnancy: See guidance
No established RDA. Small trials suggest possible preeclampsia prevention benefit. Generally considered safe at 100–200 mg/day, but data are limited. Consult obstetric provider [3].
👦 Pediatric: See guidance
Primary CoQ10 deficiency presenting in childhood (nephrotic syndrome, cerebellar ataxia, encephalomyopathy) is treated with 5–30 mg/kg/day — early treatment can prevent irreversible organ damage [
🏃 Athletes: Standard dose
⚖️ Obesity: Standard dose
Fat-soluble compounds may require dose adjustment in obesity.
🩺 Renal: Consult specialist
Dose adjustment may be needed in renal impairment.
🌱 Vegan: Standard dose

How to take

🍽 Timing: Take with a meal containing fat — absorption improves 3-fold with food vs fasting [3].
💊 With food: Take with the largest meal of the day or a meal containing olive oil, nuts, or avocado [3].
🚫 Avoid: Monitor INR if combining with warfarin [3]. Avoid very high doses (>600 mg/day) without medical supervision [3].
2 Which form?
FormBioavailabilityVeganCost
['Ubiquinone (oxidized CoQ10)', 'common', 'Standard supplemental form. Must be reduced to ubiquinol in the body to function as an antioxidant. Well-studied. Lower cost [1].']StandardCheck label
['Ubiquinol (reduced CoQ10)', 'preferred', 'The bioactive, reduced form. Approximately 2–3× greater bioavailability than ubiquinone. May be preferred in elderly or individuals with impaired reduction capacity (heart failure, liver disease) [3].']StandardCheck label
['Solubilized/nano-formulations', '', 'Various formulations using cyclodextrin, liposomes, or oil-based soft gels to enhance absorption. Bioavailability varies by product [3].']StandardCheck label
3 Common questions
Should I take CoQ10 if I'm on a statin?
This is the most common question and remains debated. Statins do reduce CoQ10 synthesis by 20–40% [2]. Some meta-analyses suggest CoQ10 modestly reduces statin-related muscle symptoms, but results are inconsistent [8]. There is no universal guideline recommending routine CoQ10 with statins. It is reasonable to try 100–200 mg/day if experiencing statin-related muscle symptoms.
Is ubiquinol better than ubiquinone?
Ubiquinol (the reduced form) has approximately 2–3× greater bioavailability than ubiquinone [3]. It may be preferred in elderly patients, heart failure, or those not responding to ubiquinone. However, both forms are converted back and forth in the body, and ubiquinone is well-studied and effective in clinical trials (including Q-SYMBIO, which used ubiquinone).
Does CoQ10 help heart failure?
The Q-SYMBIO trial (n = 420) showed 43% reduction in MACE and 42% reduction in mortality with 300 mg/day over 2 years [5]. This is the strongest clinical trial evidence. However, it was a single trial and not yet replicated at scale. Current ESC/AHA heart failure guidelines do not formally recommend CoQ10, but some cardiologists use it as adjunctive therapy.
Can CoQ10 treat Parkinson disease?
Despite early promise, the definitive QE3 Phase III trial (n = 600) showed no benefit of CoQ10 at any dose (1,200 or 2,400 mg/day) versus placebo for early Parkinson disease [6]. It is not recommended for this indication.
4 Clinical evidence

Strong

Essential role in mitochondrial electron transport chain — genetic primary CoQ10 deficiency causes encephalomyopathy, nephrotic syndrome, and cerebellar ataxia, treated with high-dose CoQ10 supplementation [4]. Statins inhibit CoQ10 synthesis via mevalonate pathway suppression — this is well-established biochemically [2]. HIGH

Moderate

Heart failure: the Q-SYMBIO trial (n = 420, randomized, double-blind) showed that CoQ10 300 mg/day reduced major adverse cardiovascular events by 43% and all-cause mortality by 42% over 2 years [5]. Statin-associated myopathy: meta-analysis of 12 RCTs showed modest reduction in statin-related muscle symptoms with CoQ10 supplementation, though results are inconsistent [8]. Migraine prevention: a small RCT (n = 42) showed CoQ10 300 mg/day reduced migraine frequency by 48% vs 14% placebo [3]. Preeclampsia prevention: a small trial showed reduced risk with CoQ10 supplementation from 20 weeks gestation [3]. MODERATE

Insufficient

Parkinson disease: the QE3 Phase III trial (n = 600) found no benefit of CoQ10 at 1,200 or 2,400 mg/day vs placebo for early PD [6]. Athletic performance in healthy individuals: no convincing benefit [3]. Male fertility: some positive small studies but insufficient for recommendation [3]. Huntington disease: no benefit in Phase III trial [3]. LOW
5 Safety, toxicity & adverse events

Relative

⚠ Concurrent warfarin — CoQ10 has structural similarity to vitamin K; may reduce INR (monitor closely)
⚠ Concurrent antihypertensives — CoQ10 may lower blood pressure 11/7 mmHg (additive)
⚠ Concurrent chemotherapy — theoretical concern about antioxidant protection of tumor cells (discuss with oncologist)
⚠ Concurrent insulin/sulfonylureas — CoQ10 may improve insulin sensitivity (monitor glucose)

🚩 Red flags

Warfarin patient starting CoQ10 — check INR within 1–2 weeks (structural similarity to vitamin K) [3]
Child with steroid-resistant nephrotic syndrome — consider primary CoQ10 deficiency (genetic testing) [4]
Patient attributing statin intolerance solely to CoQ10 depletion and refusing statins — important to distinguish myalgia from true myopathy; statins save lives [2]
6 Interactions

Drug interactions

Warfarin Major
Mechanism: CoQ10 (ubiquinone) is structurally similar to vitamin K₂. May promote coagulation and reduce warfarin efficacy. [3]
Effect: Reduced INR. Potential thromboembolic events if warfarin dose is not adjusted. [3]
Action: Check INR within 1–2 weeks of starting CoQ10. Monitor closely with dose changes [3].
Statins (atorvastatin, rosuvastatin, etc.) Moderate
Mechanism: Statins inhibit HMG-CoA reductase (mevalonate pathway), reducing endogenous CoQ10 synthesis by 20–40%. [2]
Effect: Reduced plasma CoQ10. Possible contribution to statin myopathy. [2]
Action: CoQ10 100–200 mg/day is reasonable if statin-associated muscle symptoms occur [8].
Antihypertensives Minor
Mechanism: CoQ10 may have modest blood pressure lowering effects (meta-analyses suggest ~3–5 mmHg systolic reduction). [3]
Effect: Additive blood pressure reduction; risk of hypotension in patients on multiple antihypertensives. [3]
Action: Monitor blood pressure, especially during dose adjustments [3].
Chemotherapy agents (doxorubicin) Moderate
Mechanism: Doxorubicin causes cardiotoxicity partly via mitochondrial damage and ROS. CoQ10 is cardioprotective in animal models. [1]
Effect: Potential cardioprotection. Theoretical concern about reducing chemotherapy efficacy (antioxidant interference), though clinical data are limited. [1]
Action: Discuss with oncologist before supplementing during chemotherapy [1].

Supplement synergies

Vitamin E · 15 mg/day vitamin E (RDA)
CoQ10 regenerates oxidized vitamin E (alpha-tocopherol) back to its active form, and both protect cell membranes from lipid peroxidation [1].
Selenium · 100–200 µg/day selenium
The KiSel-10 trial showed that combined selenium + CoQ10 supplementation (200 µg Se + 200 mg CoQ10) reduced cardiovascular mortality by 49% in elderly Swedish adults over 5 years [3].
Alpha-Lipoic Acid · 300–600 mg/day ALA
Both are mitochondrial antioxidants. ALA regenerates CoQ10 in the mitochondrial membrane [1].
7 Regulatory
United States (FDA): Classified as a dietary supplement. No RDA established (endogenously synthesized). No FDA-approved health claims. Marketed for heart health and energy [1].
European Union (EFSA): No authorized health claims. Classified as a food supplement. Widely available OTC across Europe [3].
Japan (MHLW): CoQ10 was a prescription drug in Japan until 2001 (for heart failure). Now available as a food supplement. One of the most popular supplements in Japan [3].
South Korea (MFDS): Available as dietary supplement. Approved claims: antioxidant activity.
8 US supplement products
43
on-market products containing Coenzyme Q10 (NIH DSLD)

Brands carrying Coenzyme Q10 (16)

Click a brand to see its Coenzyme Q10 products.
Or browse all 43 products in one list →
9 Frequently paired with
Vitamin E 14 shared
Coenzyme Q10 vs Vitamin ECoenzyme Q10 vs Selenium
10 Cite this page
Vancouver: Pkhakadze G. Coenzyme Q10 — safety profile [Internet]. Tbilisi: PHIG; 2026 [cited 2026 Jul 12]. Available from: https://supplement.ge/ingredients/coenzyme-q10/
APA 7th: Pkhakadze, G. (2026). Coenzyme Q10 — Safety profile. Public Health Institute of Georgia. https://supplement.ge/ingredients/coenzyme-q10/
📋 Editorial information
Author: Prof. G. Pkhakadze, MD, MPH, PhD
Affiliation: David Tvildiani Medical University (DTMU)
First published: January 2026
Last reviewed: 2026-05-29
Next review: January 2027
References: 8 cited sources
COI: SupplementIndex receives no funding from supplement manufacturers. All content independently authored by PHIG.
Process: Systematic literature review
📄 License & reuse
Published under Creative Commons Attribution 4.0 International (CC BY 4.0). You may share and adapt for any purpose with attribution.
Pkhakadze G. "Coenzyme Q10 — Safety Profile." SupplementIndex, PHIG, 2026. https://supplement.ge/ingredients/coenzyme-q10/ CC BY 4.0.
GP
Prof. G. Pkhakadze, MD, MPH, PhD
Professor of Public Health · Head of Department, DTMU
Editor-in-Chief, Georgian Medical Journal (ISSN 3088-4322)
Chair, Public Health Institute of Georgia · UEMS Public Health Section
Educational and public health purposes. CC BY 4.0. Consult your healthcare provider before starting any supplement. Corrections: info@accreditation.ge. Publisher: PHIG